Human Integrin alpha V beta 5 (ITGAV&ITGB5) Heterodimer Protein, His Tag&Tag Free
分子别名(Synonym)
Integrin alpha V beta 5,ITGAV&ITGB5
表达区间及表达系统(Source)
Human ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag Free (IT5-H52W5) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 24 - Asn 719 (ITGB5) (Accession # NP_002201.1 (ITGAV) & NP_002204.2 (ITGB5)).
Predicted N-terminus: Phe 31 (ITGAV) & Gly 24 (ITGB5)
蛋白结构(Molecular Characterization)
Human ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB5, has a calculated MW of 112.9 kDa (ITGAV) and 81.9 kDa (ITGB5). Subunit ITGAV is fused with polyhistidine tag at the C-terminus and followed by a acidic tail and subunit ITGB5 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 130-150 kDa (ITGAV) and 85-95 kDa (ITGB5) respectively due to glycosylation.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
整合素αVβ5(ITGAV和ITGB5)在多种细胞类型上表达,包括角质形成细胞、成纤维细胞、粘附性单核细胞、胚胎干细胞以及特定的内皮和上皮细胞。ITGAV和ITGB5结合含有RGD基序的配体,特别是玻连蛋白。增加PKC活性的生长因子,如VEGF或TGF-α,促进ITGAV和ITGB5介导的血管生成,而可能在同一细胞中表达的αVβ3对FGF碱性和TNF-α有反应。两者的抑制剂都能下调肿瘤血管生成。在肺部炎症期间,肌成纤维细胞或浸润淋巴细胞上ITGAV和ITGB5的上调可能通过释放TGF-β来促进纤维化。
关键字: Integrin αvβ5;整合素αvβ5;αvβ5;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。